Robert Jeanfreau

1.5k total citations
16 papers, 274 citations indexed

About

Robert Jeanfreau is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, Robert Jeanfreau has authored 16 papers receiving a total of 274 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 5 papers in Infectious Diseases and 5 papers in Microbiology. Recurrent topics in Robert Jeanfreau's work include Influenza Virus Research Studies (13 papers), Respiratory viral infections research (10 papers) and Pneumonia and Respiratory Infections (6 papers). Robert Jeanfreau is often cited by papers focused on Influenza Virus Research Studies (13 papers), Respiratory viral infections research (10 papers) and Pneumonia and Respiratory Infections (6 papers). Robert Jeanfreau collaborates with scholars based in United States, Belgium and Canada. Robert Jeanfreau's co-authors include Nicola P. Klein, Bruce L. Innis, Mandeep Singh Dhingra, Emilia Jordanov, Scott A. Halperin, Lisa Bedell, Emmanuel B. Walter, Christopher Gill, Keith S. Reisinger and Anil Kumar Gupta and has published in prestigious journals such as PEDIATRICS, The Journal of Infectious Diseases and Emerging infectious diseases.

In The Last Decade

Robert Jeanfreau

15 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Jeanfreau United States 12 245 86 77 57 44 16 274
Lotte H. Hendrikx Netherlands 11 346 1.4× 360 4.2× 105 1.4× 63 1.1× 14 0.3× 12 433
Nancy Bermal Philippines 8 410 1.7× 251 2.9× 56 0.7× 37 0.6× 50 1.1× 13 439
May ElSherif Canada 8 154 0.6× 83 1.0× 38 0.5× 14 0.2× 36 0.8× 16 197
Emilia Jordanov United States 14 396 1.6× 298 3.5× 108 1.4× 52 0.9× 90 2.0× 35 476
Elena Grigorieva Russia 7 327 1.3× 10 0.1× 160 2.1× 95 1.7× 31 0.7× 14 375
Hitt Sharma India 10 116 0.5× 58 0.7× 65 0.8× 39 0.7× 49 1.1× 28 206
Rama Kandasamy United Kingdom 7 177 0.7× 65 0.8× 43 0.6× 73 1.3× 35 0.8× 15 245
Marta Valente Pinto United Kingdom 9 152 0.6× 109 1.3× 50 0.6× 47 0.8× 16 0.4× 20 242
Cyril Jean‐Marie Martel Denmark 8 126 0.5× 8 0.1× 60 0.8× 49 0.9× 28 0.6× 22 217
Jacqueline Lawler United States 6 241 1.0× 16 0.2× 97 1.3× 17 0.3× 167 3.8× 6 269

Countries citing papers authored by Robert Jeanfreau

Since Specialization
Citations

This map shows the geographic impact of Robert Jeanfreau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Jeanfreau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Jeanfreau more than expected).

Fields of papers citing papers by Robert Jeanfreau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Jeanfreau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Jeanfreau. The network helps show where Robert Jeanfreau may publish in the future.

Co-authorship network of co-authors of Robert Jeanfreau

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Jeanfreau. A scholar is included among the top collaborators of Robert Jeanfreau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Jeanfreau. Robert Jeanfreau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Rosas, Iván O., James A. McKinnell, Reena Shah, et al.. (2025). Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia. Emerging infectious diseases. 31(6). 1158–1168.
2.
Essink, Brandon, Marten Heeringa, Robert Jeanfreau, et al.. (2022). Safety and Immunogenicity of Cell-Based Quadrivalent Influenza Vaccine: A Randomized Trial. PEDIATRICS. 150(5). 10 indexed citations
3.
Chang, Lee-Jah, Evan J. Anderson, Robert Jeanfreau, et al.. (2021). Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial. Vaccine. 39(11). 1572–1582. 1 indexed citations
4.
5.
6.
Robertson, Corwin A., et al.. (2018). Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age. The Pediatric Infectious Disease Journal. 38(3). 323–328. 14 indexed citations
7.
Jeanfreau, Robert, et al.. (2018). 2462. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Individuals 56 Years of Age and Older. Open Forum Infectious Diseases. 5(suppl_1). S738–S738. 1 indexed citations
8.
Jain, Varsha, Joseph B. Domachowske, Long Wang, et al.. (2016). Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial. Journal of the Pediatric Infectious Diseases Society. 6(1). piw068–piw068. 22 indexed citations
9.
Mufson, Maurice A., Carlos Javier Gómez Díaz, M. Leonardi, et al.. (2014). Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months. Journal of the Pediatric Infectious Diseases Society. 4(4). 339–348. 15 indexed citations
10.
Kosalaraksa, Pope, Robert Jeanfreau, Louise Frenette, et al.. (2014). AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial. The Journal of Infectious Diseases. 211(5). 801–810. 18 indexed citations
11.
Langley, Joanne M., Louise Frenette, Robert Jeanfreau, et al.. (2014). Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: A randomized controlled clinical trial. Vaccine. 33(4). 559–567. 16 indexed citations
12.
Pavía-Ruz, Noris, M Weber, YL Lau, et al.. (2013). A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Human Vaccines & Immunotherapeutics. 9(9). 1978–1988. 19 indexed citations
13.
Sheldon, Eric, Robert Jeanfreau, Joseph Sliman, et al.. (2012). Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow‐fill‐seal device in adults: a randomized, active‐controlled study*. Influenza and Other Respiratory Viruses. 7(6). 1142–1150. 13 indexed citations
14.
Greenberg, Michael E., Michael H. Lai, Günter Härtel, et al.. (2010). A Single Dose of Unadjuvanted Novel 2009 H1N1 Vaccine Is Immunogenic and Well Tolerated in Young and Elderly Adults. The Journal of Infectious Diseases. 202(9). 1327–1337. 39 indexed citations
15.
Baxter, Roger, Robert Jeanfreau, S. Block, et al.. (2010). A Phase III Evaluation of Immunogenicity and Safety of Two Trivalent Inactivated Seasonal Influenza Vaccines in US Children. The Pediatric Infectious Disease Journal. 29(10). 924–930. 16 indexed citations
16.
Halperin, Scott A., Anil Kumar Gupta, Robert Jeanfreau, et al.. (2010). Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age. Vaccine. 28(50). 7865–7872. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lotte H. Hendrikx Breakdown of academic impact, for papers by Nancy Bermal Breakdown of academic impact, for papers by May ElSherif Breakdown of academic impact, for papers by Emilia Jordanov Breakdown of academic impact, for papers by Elena Grigorieva Breakdown of academic impact, for papers by Hitt Sharma Breakdown of academic impact, for papers by Rama Kandasamy Breakdown of academic impact, for papers by Marta Valente Pinto Breakdown of academic impact, for papers by Cyril Jean‐Marie Martel Breakdown of academic impact, for papers by Jacqueline Lawler
Rankless by CCL
2026